Wall Street Wire - Wall Street Sync

Features

A Big Commercial Partner Just Backed This Small-Cap Cancer Company - and the Catalysts Keep Coming

Alpha Tau’s Tolmar partnership adds capital, commercial muscle, and fresh validation for Alpha DaRT. With prostate, pancreatic, skin-cancer, and glioblastoma catalysts advancing, the small-cap oncology story is gaining momentum.

Features

Everyone's Talking About Peptides. One Under-the-Radar Company Is Actually Building the Future of Them

Peptides are everywhere - but Entera Bio is aiming beyond the hype: turning proven injectable therapies into oral tablets, with EB613 headed toward Phase 3 as a potential first-in-class bone-building pill for osteoporosis.

Wall Street Wire

Drone Procurement Enters New Capital Cycle as Counter-UAS Market Projected to Reach $20 Billion By 2030

The Trump administration is reportedly in talks to fund U.S. drone manufacturers through the Pentagon's Office of Strategic Capital - a vehicle set for an approximately 1,247% funding increase in fiscal 2027 - while Section 1709 of the FY25 NDAA reshapes the domestic drone supply chain

Features

QTREX Quantum: A Picks-and-Shovels Position at the Cryogenic Bottleneck Holding Back Quantum Computing

QTREX, the new name in quantum, is building into the cryogenic bottleneck holding back the entire field | NASDAQ: QTEX*

Features

Nasus Pharma Is Targeting the Next Evolution of Emergency Allergy Treatment - And Wall Street Is Starting to Notice

Nasus Pharma is betting it can reinvent emergency allergy treatment with a needle-free epinephrine nasal spray - and after strong Phase II data and a new $19 Zacks price target, Wall Street may be starting to pay attention | NYSE: NSRX*